Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan.

被引：0
|
作者：
Fukuda, Koshiro
Ooki, Akira
Osumi, Hiroki
Fukuoka, Shota
Yoshino, Koichiro
Tamba, Mikako
Udagawa, Shohei
Shimozaki, Keitaro
Ogura, Mariko
Wakatsuki, Takeru
Chin, Keisho
Fujishiro, Mitsuhiro
Shinozaki, Eiji
Yamaguchi, Kensei
机构：
[1] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Tokyo, Japan
[2] Canc Inst Hosp Japanese Fdn Canc Res, Dept Gastroenterol Chemotherapy, Koto, Japan
[3] Univ Tokyo, Dept Gastroenterol, Tokyo, Japan
[4] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：360 / 360
页数：1
相关论文
共 50 条
  • [31] Trastuzumab deruxtecan versus trastuzumab emtansine in Asian patients with HER2-positive metastatic breast cancer
    Iwata, Hiroji
    Xu, Binghe
    Kim, Sung-Bae
    Chung, Wei-Pang
    Park, Yeon Hee
    Kim, Min Hwan
    Tseng, Ling-Ming
    Chung, Chi-Feng
    Huang, Chiun-Sheng
    Kim, Jee Hyun
    Chiu, Joanne Wing Yan
    Yamashita, Toshinari
    Li, Wei
    Egorov, Anton
    Nishijima, Soichiro
    Nakatani, Shunsuke
    Nishiyama, Yuji
    Sugihara, Masahiro
    Cortes, Javier
    Im, Seock-Ah
    CANCER SCIENCE, 2024, 115 (09) : 3079 - 3088
  • [32] Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab
    Che, Yi-Qun
    Zhang, Yue
    Ou, Kai-Ping
    Wang, Di
    Shen, Di
    Liu, Hui-Ying
    Luo, Yang
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 8527 - 8534
  • [33] Safety of trastuzumab deruxtecan and radiation therapy in HER2-positive breast cancer patients
    Visani, Luca
    Ratosa, Ivica
    Ribnikar, Domen
    Becherini, Carlotta
    Bertini, Niccolo
    Bonaparte, Ilaria
    Stefanovski, Dimitar
    Dobnikar, Nika
    Desideri, Isacco
    Olmetto, Emanuela
    Mangoni, Monica
    Di Cataldo, Vanessa
    Peruzzi, Anna
    Mattioli, Chiara
    Cela, Doruntina
    Valzano, Marianna
    Salvestrini, Viola
    Scoccimarro, Erika
    Livi, Lorenzo
    Meattini, Icro
    RADIOTHERAPY AND ONCOLOGY, 2024, 194 : S691 - S692
  • [34] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [35] Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer: a plain language summary of the DESTINY-Gastric01 study
    Shitara, Kohei
    FUTURE ONCOLOGY, 2024, 20 (02) : 59 - 70
  • [36] Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer
    Mark Sanford
    Drugs, 2013, 73 : 1605 - 1615
  • [37] Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 421 - 422
  • [38] Trastuzumab: A Review of Its Use in HER2-Positive Advanced Gastric Cancer
    Sanford, Mark
    DRUGS, 2013, 73 (14) : 1605 - 1615
  • [39] The efficacy and safety of trastuzumab for unresectable advanced HER2-positive gastric cancer
    Matsueda, Katsunori
    Toyokawa, Tatsuya
    Horii, Joichiro
    Fujita, Isao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2015, 30 : 95 - 95
  • [40] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
    Shitara, Kohei
    Iwata, Hiroji
    Takahashi, Shunji
    Tamura, Kenji
    Park, Haeseong
    Modi, Shanu
    Tsurutani, Junji
    Kadowaki, Shigenon
    Yamaguchi, Kensei
    Iwasa, Satoru
    Saito, Kaku
    Fujisaki, Yoshihiko
    Sugihara, Masahiro
    Shahidi, Javad
    Doi, Toshihiko
    LANCET ONCOLOGY, 2019, 20 (06): : 827 - 836
12345